Why the US Is Paying $486 Million to Test AstraZeneca’s COVID-19 Drug Cocktail 24/7 Wall Street • 10/12/20
AstraZeneca Secures $486 Million From U.S. Government for Coronavirus Antibody CocktailThe Motley Fool • 10/09/20
FDA to require 2-month follow-up period for COVID-19 vaccines before authorizationMarket Watch • 10/06/20
EU Regulators Undertake Rolling Review of Another Coronavirus Vaccine CandidateThe Motley Fool • 10/06/20
AstraZeneca's Coronavirus Vaccine Is Already Being Reviewed for Approval in Canada and Europe. Why Not in the U.S.?The Motley Fool • 10/06/20
COVID-19 Vaccine Makers AstraZeneca, GSK To Get First Access To Nvidia's 'Cambridge-1' SupercomputerBenzinga • 10/06/20
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/05/20
Everything Investors Need to Know About Investigational New Drug SubmissionsThe Motley Fool • 10/03/20
Canada Begins Reviewing AstraZeneca's Coronavirus Vaccine, U.S. Study Still Not RestartedThe Motley Fool • 10/02/20
European Regulators Begin Accelerated Review of AstraZeneca's COVID-19 Vaccine Candidate, but FDA Widens Its Investigation Into Clinical Trial IllnessThe Motley Fool • 10/01/20
AstraZeneca's COVID-19 Vaccine Trial Delays May Worsen As FDA Widens InvestigationBenzinga • 10/01/20